Copyright Reports & Markets. All rights reserved.

Global Fabrazyme (agalsidase beta) Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024

Request for Sample of this report
Buy now

Table of Contents

    1 Market Overview

    • 1.1 Fabrazyme (agalsidase beta) Introduction
    • 1.2 Market Analysis by Type
      • 1.2.1 5mg/vial
      • 1.2.2 35mg/vial
    • 1.3 Market Analysis by Applications
      • 1.3.1 Hospital
      • 1.3.2 Drug store
    • 1.4 Market Analysis by Regions
      • 1.4.1 North America (United States, Canada and Mexico)
        • 1.4.1.1 United States Market States and Outlook (2013-2023)
        • 1.4.1.2 Canada Market States and Outlook (2013-2023)
        • 1.4.1.3 Mexico Market States and Outlook (2013-2023)
      • 1.4.2 Europe (Germany, France, UK, Russia and Italy)
        • 1.4.2.1 Germany Market States and Outlook (2013-2023)
        • 1.4.2.2 France Market States and Outlook (2013-2023)
        • 1.4.2.3 UK Market States and Outlook (2013-2023)
        • 1.4.2.4 Russia Market States and Outlook (2013-2023)
        • 1.4.2.5 Italy Market States and Outlook (2013-2023)
      • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
        • 1.4.3.1 China Market States and Outlook (2013-2023)
        • 1.4.3.2 Japan Market States and Outlook (2013-2023)
        • 1.4.3.3 Korea Market States and Outlook (2013-2023)
        • 1.4.3.4 India Market States and Outlook (2013-2023)
        • 1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
      • 1.4.4 South America, Middle East and Africa
        • 1.4.4.1 Brazil Market States and Outlook (2013-2023)
        • 1.4.4.2 Egypt Market States and Outlook (2013-2023)
        • 1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
        • 1.4.4.4 South Africa Market States and Outlook (2013-2023)
        • 1.4.4.5 Nigeria Market States and Outlook (2013-2023)
    • 1.5 Market Dynamics
      • 1.5.1 Market Opportunities
      • 1.5.2 Market Risk
      • 1.5.3 Market Driving Force

    2 Manufacturers Profiles

    • 2.1 Genzyme Corporation
      • 2.1.1 Business Overview
      • 2.1.2 Fabrazyme (agalsidase beta) Type and Applications
        • 2.1.2.1 Product A
        • 2.1.2.2 Product B
      • 2.1.3 Genzyme Corporation Fabrazyme (agalsidase beta) Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

    3 Global Fabrazyme (agalsidase beta) Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

    • 3.1 Global Fabrazyme (agalsidase beta) Sales and Market Share by Manufacturer (2016-2017)
    • 3.2 Global Fabrazyme (agalsidase beta) Revenue and Market Share by Manufacturer (2016-2017)
    • 3.3 Market Concentration Rate
      • 3.3.1 Top 3 Fabrazyme (agalsidase beta) Manufacturer Market Share in 2017
      • 3.3.2 Top 6 Fabrazyme (agalsidase beta) Manufacturer Market Share in 2017
    • 3.4 Market Competition Trend

    4 Global Fabrazyme (agalsidase beta) Market Analysis by Regions

    • 4.1 Global Fabrazyme (agalsidase beta) Sales, Revenue and Market Share by Regions
      • 4.1.1 Global Fabrazyme (agalsidase beta) Sales and Market Share by Regions (2013-2018)
      • 4.1.2 Global Fabrazyme (agalsidase beta) Revenue and Market Share by Regions (2013-2018)
    • 4.2 North America Fabrazyme (agalsidase beta) Sales and Growth Rate (2013-2018)
    • 4.3 Europe Fabrazyme (agalsidase beta) Sales and Growth Rate (2013-2018)
    • 4.4 Asia-Pacific Fabrazyme (agalsidase beta) Sales and Growth Rate (2013-2018)
    • 4.5 South America Fabrazyme (agalsidase beta) Sales and Growth Rate (2013-2018)
    • 4.6 Middle East and Africa Fabrazyme (agalsidase beta) Sales and Growth Rate (2013-2018)

    5 North America Fabrazyme (agalsidase beta) by Countries

    • 5.1 North America Fabrazyme (agalsidase beta) Sales, Revenue and Market Share by Countries
      • 5.1.1 North America Fabrazyme (agalsidase beta) Sales and Market Share by Countries (2013-2018)
      • 5.1.2 North America Fabrazyme (agalsidase beta) Revenue and Market Share by Countries (2013-2018)
    • 5.2 United States Fabrazyme (agalsidase beta) Sales and Growth Rate (2013-2018)
    • 5.3 Canada Fabrazyme (agalsidase beta) Sales and Growth Rate (2013-2018)
    • 5.4 Mexico Fabrazyme (agalsidase beta) Sales and Growth Rate (2013-2018)

    6 Europe Fabrazyme (agalsidase beta) by Countries

    • 6.1 Europe Fabrazyme (agalsidase beta) Sales, Revenue and Market Share by Countries
      • 6.1.1 Europe Fabrazyme (agalsidase beta) Sales and Market Share by Countries (2013-2018)
      • 6.1.2 Europe Fabrazyme (agalsidase beta) Revenue and Market Share by Countries (2013-2018)
    • 6.2 Germany Fabrazyme (agalsidase beta) Sales and Growth Rate (2013-2018)
    • 6.3 UK Fabrazyme (agalsidase beta) Sales and Growth Rate (2013-2018)
    • 6.4 France Fabrazyme (agalsidase beta) Sales and Growth Rate (2013-2018)
    • 6.5 Russia Fabrazyme (agalsidase beta) Sales and Growth Rate (2013-2018)
    • 6.6 Italy Fabrazyme (agalsidase beta) Sales and Growth Rate (2013-2018)

    7 Asia-Pacific Fabrazyme (agalsidase beta) by Countries

    • 7.1 Asia-Pacific Fabrazyme (agalsidase beta) Sales, Revenue and Market Share by Countries
      • 7.1.1 Asia-Pacific Fabrazyme (agalsidase beta) Sales and Market Share by Countries (2013-2018)
      • 7.1.2 Asia-Pacific Fabrazyme (agalsidase beta) Revenue and Market Share by Countries (2013-2018)
    • 7.2 China Fabrazyme (agalsidase beta) Sales and Growth Rate (2013-2018)
    • 7.3 Japan Fabrazyme (agalsidase beta) Sales and Growth Rate (2013-2018)
    • 7.4 Korea Fabrazyme (agalsidase beta) Sales and Growth Rate (2013-2018)
    • 7.5 India Fabrazyme (agalsidase beta) Sales and Growth Rate (2013-2018)
    • 7.6 Southeast Asia Fabrazyme (agalsidase beta) Sales and Growth Rate (2013-2018)

    8 South America Fabrazyme (agalsidase beta) by Countries

    • 8.1 South America Fabrazyme (agalsidase beta) Sales, Revenue and Market Share by Countries
      • 8.1.1 South America Fabrazyme (agalsidase beta) Sales and Market Share by Countries (2013-2018)
      • 8.1.2 South America Fabrazyme (agalsidase beta) Revenue and Market Share by Countries (2013-2018)
    • 8.2 Brazil Fabrazyme (agalsidase beta) Sales and Growth Rate (2013-2018)
    • 8.3 Argentina Fabrazyme (agalsidase beta) Sales and Growth Rate (2013-2018)
    • 8.4 Colombia Fabrazyme (agalsidase beta) Sales and Growth Rate (2013-2018)

    9 Middle East and Africa Fabrazyme (agalsidase beta) by Countries

    • 9.1 Middle East and Africa Fabrazyme (agalsidase beta) Sales, Revenue and Market Share by Countries
      • 9.1.1 Middle East and Africa Fabrazyme (agalsidase beta) Sales and Market Share by Countries (2013-2018)
      • 9.1.2 Middle East and Africa Fabrazyme (agalsidase beta) Revenue and Market Share by Countries (2013-2018)
    • 9.2 Saudi Arabia Fabrazyme (agalsidase beta) Sales and Growth Rate (2013-2018)
    • 9.3 UAE Fabrazyme (agalsidase beta) Sales and Growth Rate (2013-2018)
    • 9.4 Egypt Fabrazyme (agalsidase beta) Sales and Growth Rate (2013-2018)
    • 9.5 Nigeria Fabrazyme (agalsidase beta) Sales and Growth Rate (2013-2018)
    • 9.6 South Africa Fabrazyme (agalsidase beta) Sales and Growth Rate (2013-2018)

    10 Global Fabrazyme (agalsidase beta) Market Segment by Type

    • 10.1 Global Fabrazyme (agalsidase beta) Sales, Revenue and Market Share by Type (2013-2018)
      • 10.1.1 Global Fabrazyme (agalsidase beta) Sales and Market Share by Type (2013-2018)
      • 10.1.2 Global Fabrazyme (agalsidase beta) Revenue and Market Share by Type (2013-2018)
    • 10.2 5mg/vial Sales Growth and Price
      • 10.2.1 Global 5mg/vial Sales Growth (2013-2018)
      • 10.2.2 Global 5mg/vial Price (2013-2018)
    • 10.3 35mg/vial Sales Growth and Price
      • 10.3.1 Global 35mg/vial Sales Growth (2013-2018)
      • 10.3.2 Global 35mg/vial Price (2013-2018)

    11 Global Fabrazyme (agalsidase beta) Market Segment by Application

    • 11.1 Global Fabrazyme (agalsidase beta) Sales Market Share by Application (2013-2018)
    • 11.2 Hospital Sales Growth (2013-2018)
    • 11.3 Drug store Sales Growth (2013-2018)

    12 Fabrazyme (agalsidase beta) Market Forecast (2018-2023)

    • 12.1 Global Fabrazyme (agalsidase beta) Sales, Revenue and Growth Rate (2018-2023)
    • 12.2 Fabrazyme (agalsidase beta) Market Forecast by Regions (2018-2023)
      • 12.2.1 North America Fabrazyme (agalsidase beta) Market Forecast (2018-2023)
      • 12.2.2 Europe Fabrazyme (agalsidase beta) Market Forecast (2018-2023)
      • 12.2.3 Asia-Pacific Fabrazyme (agalsidase beta) Market Forecast (2018-2023)
      • 12.2.4 South America Fabrazyme (agalsidase beta) Market Forecast (2018-2023)
      • 12.2.5 Middle East and Africa Fabrazyme (agalsidase beta) Market Forecast (2018-2023)
    • 12.3 Fabrazyme (agalsidase beta) Market Forecast by Type (2018-2023)
      • 12.3.1 Global Fabrazyme (agalsidase beta) Sales Forecast by Type (2018-2023)
      • 12.3.2 Global Fabrazyme (agalsidase beta) Market Share Forecast by Type (2018-2023)
    • 12.4 Fabrazyme (agalsidase beta) Market Forecast by Application (2018-2023)
      • 12.4.1 Global Fabrazyme (agalsidase beta) Sales Forecast by Application (2018-2023)
      • 12.4.2 Global Fabrazyme (agalsidase beta) Market Share Forecast by Application (2018-2023)

    13 Sales Channel, Distributors, Traders and Dealers

    • 13.1 Sales Channel
      • 13.1.1 Direct Marketing
      • 13.1.2 Indirect Marketing
      • 13.1.3 Marketing Channel Future Trend
    • 13.2 Distributors, Traders and Dealers

    14 Research Findings and Conclusion

      15 Appendix

      • 15.1 Methodology

      Fabrazyme® (agalsidase beta) is used to treat patients with Fabry disease. Fabrazyme lowers the amount of a substance called globotriaosylceramide (GL-3), which builds up in cells lining the blood vessels of the kidney and certain other cells.

      Scope of the Report:
      The worldwide market for Fabrazyme (agalsidase beta) is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
      This report focuses on the Fabrazyme (agalsidase beta) in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

      Market Segment by Manufacturers, this report covers
      Genzyme Corporation

      Market Segment by Regions, regional analysis covers
      North America (United States, Canada and Mexico)
      Europe (Germany, France, UK, Russia and Italy)
      Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
      South America (Brazil, Argentina, Colombia etc.)
      Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

      Market Segment by Type, covers
      5mg/vial
      35mg/vial

      Market Segment by Applications, can be divided into
      Hospital
      Drug store

      There are 15 Chapters to deeply display the global Fabrazyme (agalsidase beta) market.
      Chapter 1, to describe Fabrazyme (agalsidase beta) Introduction, product scope, market overview, market opportunities, market risk, market driving force;
      Chapter 2, to analyze the top manufacturers of Fabrazyme (agalsidase beta), with sales, revenue, and price of Fabrazyme (agalsidase beta), in 2016 and 2017;
      Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
      Chapter 4, to show the global market by regions, with sales, revenue and market share of Fabrazyme (agalsidase beta), for each region, from 2013 to 2018;
      Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
      Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
      Chapter 12, Fabrazyme (agalsidase beta) market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
      Chapter 13, 14 and 15, to describe Fabrazyme (agalsidase beta) sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

      Buy now